Please Wait
Applying Filters...
menu
    • menu
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Elraglusib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Actuate Therapeutics Reveals Doubling Survival Rate
    Actuate Therapeutics Reveals Doubling Survival Rate

    14 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/14/3273413/0/en/Actuate-Therapeutics-Announces-Nature-Medicine-Publication-of-Clinical-Trial-Results-Showing-Doubling-of-the-Rate-of-Survival-with-Elraglusib-Plus-Chemotherapy-in-Previously-Untrea.html

    GLOBENEWSWIRE
    14 Apr 2026
    Share Share
    Actuate Therapeutics Set For $200M+ Pediatric Priority Review
    Actuate Therapeutics Set For $200M+ Pediatric Priority Review

    24 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-24/actuate-therapeutics-poised-for-potential-200mplus-pediatric-priority-review-vouchers-and-transformat

    PHARMIWEB
    24 Mar 2026
    Share Share
    Actuate Studies Elraglusib With RAS Inhibitors
    Actuate Studies Elraglusib With RAS Inhibitors

    09 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/09/3251848/0/en/Actuate-Therapeutics-Launches-Strategic-Research-Initiative-to-Combine-Elraglusib-with-RAS-Inhibitors.html

    GLOBENEWSWIRE
    09 Mar 2026
    Share Share
    Actuate Expands Pipeline with Elraglusib Ph 1/2 Program in Cancer
    Actuate Expands Pipeline with Elraglusib Ph 1/2 Program in Cancer

    21 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/21/3222807/0/en/Actuate-Therapeutics-Announces-Plans-to-Expand-Clinical-Pipeline-Advancing-Elraglusib-Tablet-into-a-Phase-1-2-Clinical-Program-in-Refractory-Cancers.html

    GLOBENEWSWIRE
    21 Jan 2026
    Share Share
    Actuate Therapeutics Shows Extended Survival Benefit
    Actuate Therapeutics Shows Extended Survival Benefit

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216938/0/en/Actuate-Therapeutics-Reports-Positive-Follow-Up-Data-from-its-Randomized-Controlled-Phase-2-Trial-Demonstrating-Extended-Long-Term-Overall-Survival-Benefit-with-Elraglusib-Plus-Che.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    ASCO GI 2026 Selects Actuate's Phase 2 Data for Presentation
    ASCO GI 2026 Selects Actuate's Phase 2 Data for Presentation

    18 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/18/3207741/0/en/Actuate-Therapeutics-Phase-2-Metastatic-Pancreatic-Cancer-Data-Selected-for-Oral-and-Poster-Presentation-at-ASCO-GI-2026.html

    GLOBENEWSWIRE
    18 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.